We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Two Simple Serum Biomarkers Differentiate Lymphoma from Glioma

By LabMedica International staff writers
Posted on 22 Apr 2022
Image: Micrograph of brain tissue with glioma enlargement and disease histology (Photo courtesy of 123rf.com)
Image: Micrograph of brain tissue with glioma enlargement and disease histology (Photo courtesy of 123rf.com)

A recent study found that two simple serum biomarkers, absolute lymphocyte count and prognostic nutritional index, which are easily derived from routine pre-treatment blood tests, have fair correlation and acceptable diagnostic accuracy for differentiating primary central nervous system lymphoma (PCNSL) from high-grade glioma (HGG) in patients with similar morphology on MRI.

A complex series of interactions take place between cancer and inflammation that are reflected by increased release of inflammatory biomarkers into the bloodstream. However, the utility of systemic inflammatory biomarkers as a means for the noninvasive differential diagnosis of PCNSL from HCC is generally lacking.

To repair this lack, investigators at the Homi Bhabha National Institute (Mumbai, India) and their colleagues carried out a study that involved calculating systemic inflammatory indices from pre-treatment complete blood counts and liver function tests and comparing them against histopathology as the reference standard among 42 patients with PCNSL and 16 with HGG.

Results revealed that the area under the receiver operating characteristics curve for absolute lymphocyte count and prognostic nutritional index in the diagnosis of PCNSL was 0.70 and 0.72 respectively, which suggested that these markers yielded fair and acceptable diagnostic accuracy.

The investigators said, "This exploratory first-of-a kind study assessed the utility of systemic inflammatory biomarkers derived from routine blood investigations in a cohort of patients with suspected PCNSL to differentiate them reliably from HGG with similar morphologic imaging."

The study was published in the April 4, 2022, online edition of the journal CNS Oncology.

Related Links:
Homi Bhabha National Institute 

New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Host Response Immunoassay Test
MeMed BV
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G

DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
PURITAN MEDICAL